NuScale Power Corporation (NYSE: SMR) Chief Financial Officer Robert Ramsey Hamady sold 20,000 Class A Common shares on June 30, 2026, following an option exercise, according to an SEC Form 4 filing.
The transaction was executed at a weighted average sell price of $10.14 per share on July 1, 2026, placing the total value of the sale at approximately $202,800.
Crucially, the sale was not a discretionary open-market transaction, which is a distinction that carries significant weight for investors assessing insider sentiment.
The shares were disposed of immediately following the exercise of 20,000 options, meaning Hamady did not choose to sell based on any market view or internal knowledge.
The sale was automatically triggered through a Rule 10b5-1 trading plan, a pre-scheduled arrangement that Hamady adopted back in March 2026.
These plans are commonly used by corporate insiders to execute trades on a fixed schedule, removing any appearance of trading on material non-public information.
NuScale’s stock was under pressure at the time of the sale, and the weakness continued after the transaction, with shares hitting a 52-week low of $8.55 on July 8, just days after Hamady’s disposition.
Despite the sale, Hamady retained more than 97,000 directly-held shares following the transaction, along with 165,625 stock options, indicating he maintains a meaningful and ongoing financial stake in the company.
The broader backdrop for NuScale has been challenging, with the company reporting first-quarter revenue of just $565,000, a dramatic decline from the $13.4 million generated in the first quarter of 2025.
That revenue collapse has weighed heavily on investor confidence, though analysts tracking the small modular reactor sector continue to watch NuScale closely as nuclear energy interest grows globally.
The combination of a pre-scheduled trading plan, retained equity holdings, and ongoing option positions suggests the CFO’s sale reflects personal financial planning rather than any broader negative signal about the company’s prospects.
Investors should interpret the transaction in its full context, recognizing that Rule 10b5-1 sales are a routine mechanism for executives to manage concentrated stock positions without triggering regulatory or market concerns.
